Gufic Biosciences Limited
NSE: GUFICBIO · Pharmaceuticals
Snapshot
Unlock Gufic Biosciences Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Gufic Biosciences Limited is an Indian pharmaceutical company specialising in the manufacture and marketing of active pharmaceutical ingredients (APIs), bulk drugs, and lyophilized injections. Its diverse portfolio spans critical care, infertility, and herbal products, serving both domestic hospital chains and international markets.
Business Model
The company generates revenue through the production and sale of specialised pharmaceutical formulations and APIs, leveraging its expertise in lyophilisation technology. It operates a B2B and B2C model, supplying medical facilities and hospital chains while maintaining an export presence in over 20 countries.
- Export Presence:20+ countries
- Founded:1970
Growth Outlook
Growth is driven by the expansion of its critical care and infertility product segments, alongside the scaling of its lyophilised injection manufacturing capabilities. The company continues to focus on strengthening its international footprint to diversify revenue streams.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from domestic and international health authorities, where non-compliance could lead to product recalls or manufacturing bans.
- Input Cost Volatility. Fluctuations in the prices of raw materials and APIs can significantly impact operating margins due to the company's reliance on chemical supply chains.
- Competitive Pressure. The pharmaceutical sector is highly fragmented, exposing the company to intense price competition from both domestic generic manufacturers and multinational corporations.
- Currency Risk. As an exporter to over 20 countries, the company is exposed to foreign exchange volatility which may affect the profitability of international sales.
Start your research today
Unlock AI insights, financials, peers and live data on Gufic Biosciences Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹981 Cr
TTM · consolidated
NET PROFIT
₹73 Cr
TTM · consolidated
EPS
₹7.32
TTM · consolidated
RETURN ON EQUITY
11.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
16.9%
TTM · consolidated
P/E
60.8x
Q1 FY27 · consolidated
EV/EBITDA
28.7x
Q1 FY27 · consolidated
EBITDA MARGIN
17.0%
TTM · consolidated
NET PROFIT MARGIN
8.6%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.6x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Gufic Biosciences LimitedGUFICBIO | ₹4,462 Cr | 60.78 | 28.68 | 16.7% | 17.0% | 11.6% | 16.9% | +22.1% |
Orchid Pharma LimitedORCHPHARMA | ₹4,842 Cr | 592.95 | 78.06 | 10.8% | 7.1% | 0.7% | 1.5% | +32.3% |
RPG Life Sciences LimitedRPGLIFE | ₹4,501 Cr | 37.68 | 24.51 | 11.8% | 24.5% | 21.0% | 27.6% | +14.7% |
Gujarat Themis Biosyn Ltd.GUJTHEM | ₹4,482 Cr | 155.81 | 54.77 | 17.5% | 48.8% | 18.2% | 19.8% | +7.9% |
Novartis IndiaNOVARTIND | ₹4,066 Cr | 43.62 | 30.20 | -0.5% | 37.5% | 11.7% | 16.1% | +76.7% |
Aarti Drugs LimitedAARTIDRUGS | ₹3,940 Cr | 20.62 | 13.41 | — | 12.6% | 13.1% | 14.5% | -9.0% |
As of Q1 FY27
Financials
Gufic Biosciences Limited
NSE: GUFICBIO · Pharmaceuticals
Snapshot
Unlock Gufic Biosciences Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Gufic Biosciences Limited is an Indian pharmaceutical company specialising in the manufacture and marketing of active pharmaceutical ingredients (APIs), bulk drugs, and lyophilized injections. Its diverse portfolio spans critical care, infertility, and herbal products, serving both domestic hospital chains and international markets.
Business Model
The company generates revenue through the production and sale of specialised pharmaceutical formulations and APIs, leveraging its expertise in lyophilisation technology. It operates a B2B and B2C model, supplying medical facilities and hospital chains while maintaining an export presence in over 20 countries.
- Export Presence:20+ countries
- Founded:1970
Growth Outlook
Growth is driven by the expansion of its critical care and infertility product segments, alongside the scaling of its lyophilised injection manufacturing capabilities. The company continues to focus on strengthening its international footprint to diversify revenue streams.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from domestic and international health authorities, where non-compliance could lead to product recalls or manufacturing bans.
- Input Cost Volatility. Fluctuations in the prices of raw materials and APIs can significantly impact operating margins due to the company's reliance on chemical supply chains.
- Competitive Pressure. The pharmaceutical sector is highly fragmented, exposing the company to intense price competition from both domestic generic manufacturers and multinational corporations.
- Currency Risk. As an exporter to over 20 countries, the company is exposed to foreign exchange volatility which may affect the profitability of international sales.
Start your research today
Unlock AI insights, financials, peers and live data on Gufic Biosciences Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹981 Cr
TTM · consolidated
NET PROFIT
₹73 Cr
TTM · consolidated
EPS
₹7.32
TTM · consolidated
RETURN ON EQUITY
11.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
16.9%
TTM · consolidated
P/E
60.8x
Q1 FY27 · consolidated
EV/EBITDA
28.7x
Q1 FY27 · consolidated
EBITDA MARGIN
17.0%
TTM · consolidated
NET PROFIT MARGIN
8.6%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.6x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27